LID.L Regulatory News (LID)

LiDCO Group Plc

("LiDCO" or the "Company")

AGM Statement

LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, will hold its Annual General Meeting today at the offices of finnCap, 60 New Broad Street, London, EC2M 1JJ on Wednesday 11 June 2014 at 11:00am. At the meeting Terry O'Brien, Chief Executive Officer of LiDCO, will make the following statement:

I am very pleased that we will be asking shareholders to approve the Company's first Annual Report and Accounts that show a profit before tax and cash generation (before financing). Although last year saw considerable achievements against our objectives, these two achievements were a watershed moment for the Company.

As well as having a strong position in the clinical market place, the business is also now well positioned financially to deliver further growth. The Company is well-funded and we expect to be debt free by the end of the year. We look forward to continued growth in profitability and remain confident of meeting market expectations for the full year.

For further information, please contact:

About LiDCO Group Plc (www.lidco.com)

LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals, to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre. 

Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

Key Products:

LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%).

LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapid provides:

· early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug

· quantification of hemodynamic response,

· guidance on effective delivery of fluids to ensure the right amount at the right time

LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.

LiDCO Unity Software: The software incorporated into LiDCOrapid v2 allows the LiDCOrapid monitor to co-display Covidien's level of consciousness parameter and add the convenience of CNSystem's* continuous non-invasive blood pressure monitoring. This will address a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors. 

* CNAPTM is a trademark of CNSystems Medizintechnik AG.

All LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.

LiDCO Distribution Network:

LiDCO's strategy is to sell directly to hospitals in the UK and USA, and through a network of specialty critical care and anaesthesia distributors in the rest of the world.

LiDCO's sales office is in Cambridge, its manufacturing facility and headquarters are in London and its shares are traded on AIM.